Personalized medicine: individualized care of cancer patients

Translational Research

Volumn 154, Issue 6, 2009, Pages 303-308

  Ely, Scott ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ACETYLSALICYLIC ACID; ARSENIC; CHLORMETHINE; GENOMIC DNA; IBUPROFEN; IMATINIB; PARACETAMOL; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EARLY DIAGNOSIS; GASTROINTESTINAL TUMOR; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; MASTOCYTOSIS; MEDICAL PRACTICE; MEDICINE; MULTIPLE MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT INFORMATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOMICS; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SARCOMA; TREATMENT OUTCOME;

EID: 70449487356     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.08.001     Document Type: Review

References (26)

1. Thompson I.M., Lucia M.S., and Tangen C.M. Commentary. The ubiquity of prostate cancer: echoes of the past, implications for the present: "What has been will be again, what has been done will be done again; there is nothing new under the sun." ECCLESIASTES 1:9. Int J Epidemiol 36 (2007) 287-289
2. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
3. Petricoin Iii E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
4. Bach P.B., Jett J.R., Pastorino U., Tockman M.S., Swensen S.J., and Begg C.B. Computed tomography screening and lung cancer outcomes. JAMA 297 (2007) 953-961
5. Lissauer. Zwei Falle von Leucaeme Berliner Klin Wochnschr 1865;2:403-404.
6. Papac R.J. Origins of cancer therapy. Yale J Biol Med 74 (2001) 391-398
7. Weston A.D., and Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 3 (2004) 179-196
8. Macmillan L. In pursuit of personalized medicine. Reporter, Vanderbilt Medical Center's Weekly Paper (October 26, 2007) Online publication
9. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
10. Goldstein D.B. Common genetic variation and human traits. N Engl J Med 360 (2009) 1696-1698
11. Penney K.L., Salinas C.A., Pomerantz M., et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 15 (2009) 3223-3230
12. Freedman M.L., Haiman C.A., Patterson N., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103 (2006) 14068-14073
13. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1 (2002) 845-867
14. Ng M.H., Chung Y.F., Lo K.W., Wickham N.W., Lee J.C., and Huang D.P. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89 (1997) 2500-2506
15. Ely S., Di Liberto M., Niesvizky R., et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 65 (2005) 11345-11353
16. Bergsagel D.E. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?. Eur J Cancer Clin Oncol 25 (1989) 159-161
17. Kay N.E., O'Brien S.M., Pettitt A.R., and Stilgenbauer S. The role of prognostic factors in assessing "high-risk" subgroups of patients with chronic lymphocytic leukemia. Leukemia 21 (2007) 1885-1891
18. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101 (2003) 4944-4951
19. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
20. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
21. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
22. Bartlett J.M.S., Munro A., Cameron D.A., Thomas J., Prescott R., and Twelves C.J. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 26 (2008) 5027-5035
23. O'Malley F.P., Chia S., Tu D., et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 101 (2009) 644-650
24. Burton J.D., Ely S., Reddy P.K., et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 10 (2004) 6606-6611
25. Riker A.I.A.I., Radfar S.S., Liu S.S., Wang Y.Y., and Khong H.T.H.T. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7 (2007) 345-358
26. Baughn L.B., Di Liberto M., Wu K., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66 (2006) 7661-7667